Abstract:Background Liver targeting drug delivery systems can improve the curative effects and relieve the cytotoxicity of the chemotherapy drugs in the treatment of liver diseases. Nanoparticles carrying therapeutic drugs are currently under hot investigation with great clinical significance. This study was aimed to investigate the different tissue distribution of the adriamycin polybutylcyanoacrylate nanoparticle (ADM-PBCA-NP) in the mice body after an injection via lateral tail vein, and to study the liver targeting effects of ADM-PBCA-NP in different diameters on normal mice liver.Methods One hundred and eighty Kunming mice were randomly divided into 6 groups with 30 mice in each group (5 treatment groups of ADM-PBCA-NP in the different diameter ranges, non-conjugated free adriamycin injection was employed as the control group). A single dose of either conjugated or free adriamycin equaled 2 mg/kg of body weight was delivered via the tail vein. Five mice in each trail were sacrificed at 5, 15, 30 minutes, 1, 5 and 12 hours postinjection, respectively. The adriamycin concentrations in the respectively collected liver, kidney, spleen, heart, lung and plasma were demonstrated using a high performance liquid chromatography with fluorescence detector.Results Compared with the control group, adriamycin was hardly detected in the heart muscle of the treatment groups (P < 0.05). The nanoparticle-conjugated adriamycin was cleaned up quickly from the kidney tissue. The adriamycin concentrations of the mice liver and spleen in the experimental groups were significantly higher than that in the control group, except for the group with the nanoparticles diameters of (22.3 +/- 6.2) nm (P < 0.05). The ADM-PBCA-NP in (101.0 +/- 20.3) nm diameter had the highest liver distribution, and the second highest adriamycin distribution in liver was the group of (143.0 +/- 23.5) nm diameter (P < 0.05). Moreover, adriamycin was released slowly in the liver during the detection period in the experimental groups. ADM-PBCA-NP in (22.3 +/- 6.2) nm diameter was not distributed in the tissue of the liver, kidney, heart, spleen, and lung.Conclusions ADM-PBCA-NP in 100-150 nm diameter range has the best liver targeting with a characteristic of slow medicine release. It also decreases the medicine distribution in the heart, kidney and lung. In the treatment of liver cancer, the polybutylcyanoacrylate, nanoparticles system has a good liver targeting ability, which increases the anticancer activity and markedly decreases the toxicity of adriamycin.

Evaluation of in vivo Tumor Angiogenesis Targeting of Adriamycin Cationic Liposomes Coated by N-trime-thyl Chitosan

Comparison of the Anti-Tumour Activity Between N-trimethyl Chitosan-Coated Adriamycin Liposomes and Regular Adriamycin Liposomes

Preparation of Adriamycin Liposomes Coated by N-trimethyl Chitosan

Cytotoxicity of Cationic Liposomes Coated by N‐trimethyl Chitosan and Their in Vivo Tumor Angiogenesis Targeting Containing Doxorubicin

Preparation of adriamycin liposome coupled with HTf(Fe)<sub>2</sub> and its anti-tumor activity on human hepatoma cell line SMMC-7721

Preparation and Efficacy of Tumor Vasculature‐targeted Doxorubicin Cationic Liposomes Coated by N‐trimethyl Chitosan

Antitumor efficacy of adriamycin encapsulated in liposomes in mice

Anti-tumor Activity of N-trimethyl Chitosan-Encapsulated Camptothecin in a Mouse Melanoma Model.

Preparation of Adriamycin Liposomes Conjugated with VEGF and Its Targeting Action on Human Tumor-Derived Vascular Endothelial Cells in Vitro

Study on Antitumor Activity of Chitosan Chloride-Coated Hydroxycamptothecin Nanoliposomes in Mice

Liver Targeting and the Delayed Drug Release of the Nanoparticles of Adriamycin Polybutylcyanoacrylate in Mice

Preparation of the core-shell structure adriamycin lipiodol microemulsions and their synergistic anti-tumor effects with diethyldithiocarbamate in vivo.

Study on angiogenesis-targeting paramagnetic nanoliposomes in MRI for diagnosis of pulmonary carcinoma

Preparation of Adriamycin Magnetic Albumin Microspheres and Their Experimental Antitumor Effects in Vitro and in Vivo.

Enhanceing Antitumor Effect of Adriamycin Nanoparticle - Lipiodol Emulsion by Pretreating Tumor Cells with Diethyldithiocarbamate

Targeting Ability to the Vascular Endothelial Cells of N-trimethyl Chitosan-Coated Doxorubicin Liposomes in Vitro

Chitosan-Encapsulated Camptothecin in a Mouse Melanoma Model

Cytotoxicity Study of Cationic Liposomes Coated by N-trimethyl Chitosan

In Vivo Antitumor and Antimetastatic Activities of Camptothecin Encapsulated with N-Trimethyl Chitosan in A Preclinical Mouse Model of Liver Cancer

Tissue Distribution and Pharmacodynamics of Chitosan-Coated Mitoxantrone Liposomes in the Tumor-Bearing Mice

Targeting therapy of adriamycin magnetic albumin microspheres against implanted gastric tumor in rats